Genomic complexity and IGHV mutational status are key predictors of outcome of chronic lymphocytic leukemia patients with TP53 disruption.
作者信息
Delgado Julio, Salaverria Itziar, Baumann Tycho, Martínez-Trillos Alejandra, Lee Eriong, Jiménez Laura, Navarro Alba, Royo Cristina, Santacruz Rodrigo, López Cristina, Payer Angel R, Colado Enrique, González Marcos, Armengol Lluís, Colomer Dolors, Pinyol Magda, Villamor Neus, Aymerich Marta, Carrió Ana, Costa Dolors, Clot Guillem, Giné Eva, López-Guillermo Armando, Campo Elías, Beà Sílvia
机构信息
Department of Hematology, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona
Hematopathology Unit, Hospital Clínic, IDIBAPS, Barcelona.
出版信息
Haematologica. 2014 Nov;99(11):e231-4. doi: 10.3324/haematol.2014.108365. Epub 2014 Jul 4.
Abstract
摘要
相似文献
1
Genomic complexity and IGHV mutational status are key predictors of outcome of chronic lymphocytic leukemia patients with TP53 disruption.基因组复杂性和IGHV突变状态是TP53基因破坏的慢性淋巴细胞白血病患者预后的关键预测指标。
Haematologica. 2014 Nov;99(11):e231-4. doi: 10.3324/haematol.2014.108365. Epub 2014 Jul 4.
2
Major prognostic value of complex karyotype in addition to TP53 and IGHV mutational status in first-line chronic lymphocytic leukemia.除TP53和IGHV突变状态外，复杂核型在一线慢性淋巴细胞白血病中的主要预后价值。
Hematol Oncol. 2017 Dec;35(4):664-670. doi: 10.1002/hon.2349. Epub 2016 Sep 28.
3
A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes have stable disease.一部分处于比内A期、伴有TP53异常和IGHV基因突变的慢性淋巴细胞白血病患者病情稳定。
Leukemia. 2009 Jan;23(1):212-4. doi: 10.1038/leu.2008.260. Epub 2008 Sep 25.
4
Association between immunoglobulin heavy-chain variable region mutational status and isolated favorable baseline genomic aberrations in chronic lymphocytic leukemia.慢性淋巴细胞白血病中免疫球蛋白重链可变区突变状态与孤立性有利基线基因组畸变之间的关联
Leuk Lymphoma. 2018 Jan;59(1):59-68. doi: 10.1080/10428194.2017.1323271. Epub 2017 Jun 22.
5
98% IGHV gene identity is the optimal cutoff to dichotomize the prognosis of Chinese patients with chronic lymphocytic leukemia.IGHV 基因同源性 98%是将中国慢性淋巴细胞白血病患者预后进行二分的最佳截断值。
Cancer Med. 2020 Feb;9(3):999-1007. doi: 10.1002/cam4.2788. Epub 2019 Dec 17.
6
Combined analysis of IGHV mutations, telomere length and CD49d identifies long-term progression-free survivors in TP53 wild-type CLL treated with FCR-based therapies.IGHV突变、端粒长度和CD49d的联合分析可识别接受基于FCR方案治疗的TP53野生型慢性淋巴细胞白血病的长期无进展生存者。
Leukemia. 2022 Jan;36(1):271-274. doi: 10.1038/s41375-021-01322-1. Epub 2021 Jun 19.
7
The signs of negative selection in IGHV framework regions are associated with worse overall survival of chronic lymphocytic leukemia patients.IGHV 框架区负选择的迹象与慢性淋巴细胞白血病患者总体生存较差相关。
Leuk Res. 2021 Nov;110:106686. doi: 10.1016/j.leukres.2021.106686. Epub 2021 Aug 25.
8
COBLL1, LPL and ZAP70 expression defines prognostic subgroups of chronic lymphocytic leukemia patients with high accuracy and correlates with IGHV mutational status.COBLL1、LPL和ZAP70的表达能够高度准确地定义慢性淋巴细胞白血病患者的预后亚组，并且与IGHV突变状态相关。
Leuk Lymphoma. 2017 Jan;58(1):70-79. doi: 10.1080/10428194.2016.1180690. Epub 2016 May 17.
9
Association of Specific Gene Mutations with Immunoglobulin Heavy-Chain Variable Region and Chromosomal Alterations in Chronic Lymphocytic Leukemia Patients in India.印度慢性淋巴细胞白血病患者特定基因突变与免疫球蛋白重链可变区及染色体改变的关联
Asian Pac J Cancer Prev. 2025 Jan 1;26(1):109-115. doi: 10.31557/APJCP.2025.26.1.109.
10
UGT2B17 expression: a novel prognostic marker within IGHV-mutated chronic lymphocytic leukemia?UGT2B17表达：IGHV突变型慢性淋巴细胞白血病中的一种新型预后标志物？
Haematologica. 2016 Feb;101(2):e63-5. doi: 10.3324/haematol.2015.136440. Epub 2015 Nov 20.
引用本文的文献
1
Appraisal of current technologies for the study of genetic alterations in hematologic malignancies with a focus on chromosome analysis and structural variants.血液系统恶性肿瘤基因改变研究的当前技术评估，重点是染色体分析和结构变异。
Med Genet. 2024 Mar 6;36(1):13-20. doi: 10.1515/medgen-2024-2001. eCollection 2024 Apr.
2
Integrated Multi-Omic Analysis Reveals Immunosuppressive Phenotype Associated with Poor Outcomes in High-Grade Serous Ovarian Cancer.综合多组学分析揭示高级别浆液性卵巢癌中与不良预后相关的免疫抑制表型。
Cancers (Basel). 2023 Jul 17;15(14):3649. doi: 10.3390/cancers15143649.
3
Characterization of clonal immunoglobulin heavy V-D-J gene rearrangements in Chinese patients with chronic lymphocytic leukemia: Clinical features and molecular profiles.中国慢性淋巴细胞白血病患者克隆性免疫球蛋白重链V-D-J基因重排的特征：临床特征与分子图谱
Front Oncol. 2023 Feb 16;13:1120867. doi: 10.3389/fonc.2023.1120867. eCollection 2023.
4
miRNA profile at diagnosis predicts treatment outcome in patients with B-chronic lymphocytic leukemia: A FILO study.初诊时的 miRNA 谱可预测 B 慢性淋巴细胞白血病患者的治疗结局：一项 FILO 研究。
Front Immunol. 2022 Oct 17;13:983771. doi: 10.3389/fimmu.2022.983771. eCollection 2022.
5
Impact of Low-Burden Mutations in the Management of CLL.低负荷突变在慢性淋巴细胞白血病管理中的影响
Front Oncol. 2022 Feb 8;12:841630. doi: 10.3389/fonc.2022.841630. eCollection 2022.
6
"Double-Hit" Chronic Lymphocytic Leukemia, Involving the and Genes.“双打击”慢性淋巴细胞白血病，涉及 和 基因。 （你原文中这两个基因名称没写完整，请补充完整后让我翻译更准确的内容。）
Front Oncol. 2022 Jan 13;11:826245. doi: 10.3389/fonc.2021.826245. eCollection 2021.
7
Chronic lymphocytic leukemia: from molecular pathogenesis to novel therapeutic strategies.慢性淋巴细胞白血病：从分子发病机制到新型治疗策略。
Haematologica. 2020 Sep 1;105(9):2205-2217. doi: 10.3324/haematol.2019.236000.
8
Prognostic models for newly-diagnosed chronic lymphocytic leukaemia in adults: a systematic review and meta-analysis.成人新诊断慢性淋巴细胞白血病的预后模型：一项系统评价和荟萃分析。
Cochrane Database Syst Rev. 2020 Jul 31;7(7):CD012022. doi: 10.1002/14651858.CD012022.pub2.
9
Deep targeted sequencing of in chronic lymphocytic leukemia: clinical impact at diagnosis and at time of treatment.慢性淋巴细胞白血病中 的深度靶向测序：诊断时和治疗时的临床影响。
Haematologica. 2019 Apr;104(4):789-796. doi: 10.3324/haematol.2018.195818. Epub 2018 Dec 4.
10
aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics.慢性淋巴细胞白血病的畸变：诊断改进的临床意义概述。
Haematologica. 2018 Dec;103(12):1956-1968. doi: 10.3324/haematol.2018.187583. Epub 2018 Nov 15.
本文引用的文献
1
ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia.ERIC 关于慢性淋巴细胞白血病中 TP53 基因突变分析的建议。
Leukemia. 2012 Jul;26(7):1458-61. doi: 10.1038/leu.2012.25. Epub 2012 Feb 2.
2
Chronic lymphocytic leukaemia with 17p deletion: a retrospective analysis of prognostic factors and therapy results.伴有 17p 缺失的慢性淋巴细胞白血病：预后因素和治疗结果的回顾性分析。
Br J Haematol. 2012 Apr;157(1):67-74. doi: 10.1111/j.1365-2141.2011.09000.x. Epub 2012 Jan 9.
3
Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia.外显子组测序鉴定出慢性淋巴细胞白血病中剪接因子 SF3B1 基因的反复突变。
Nat Genet. 2011 Dec 11;44(1):47-52. doi: 10.1038/ng.1032.
4
SF3B1 and other novel cancer genes in chronic lymphocytic leukemia.SF3B1 及其他慢性淋巴细胞白血病中的新型癌症基因。
N Engl J Med. 2011 Dec 29;365(26):2497-506. doi: 10.1056/NEJMoa1109016. Epub 2011 Dec 12.
5
Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia.获得性基因组拷贝数异常与慢性淋巴细胞白血病患者的生存情况。
Blood. 2011 Sep 15;118(11):3051-61. doi: 10.1182/blood-2010-12-327858. Epub 2011 Jul 27.
6
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia.全基因组测序鉴定慢性淋巴细胞白血病中的反复突变。
Nature. 2011 Jun 5;475(7354):101-5. doi: 10.1038/nature10113.
7
Array-based genomic screening at diagnosis and during follow-up in chronic lymphocytic leukemia.基于阵列的基因组筛查在慢性淋巴细胞白血病诊断时和随访期间的应用。
Haematologica. 2011 Aug;96(8):1161-9. doi: 10.3324/haematol.2010.039768. Epub 2011 May 5.
8
TP53 mutation and survival in chronic lymphocytic leukemia.TP53 突变与慢性淋巴细胞白血病的生存。
J Clin Oncol. 2010 Oct 10;28(29):4473-9. doi: 10.1200/JCO.2009.27.8762. Epub 2010 Aug 9.
9
De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience.新发17p13.1缺失慢性淋巴细胞白血病表现出显著的临床异质性：纪念斯隆凯特琳癌症中心和梅奥诊所的经验
Blood. 2009 Jul 30;114(5):957-64. doi: 10.1182/blood-2009-03-210591. Epub 2009 May 4.
10
The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness.TP53突变在慢性淋巴细胞白血病中的预后价值独立于17p13缺失：对总生存期和化疗难治性的影响
Clin Cancer Res. 2009 Feb 1;15(3):995-1004. doi: 10.1158/1078-0432.CCR-08-1630.
Zotero 插件